Business

Wall Street researchers just used Claude to design a drug. The experiment has spawned a new investment thesis.

MarketWatch · October 20, 2026 at 3:35 PM

Wall Street researchers just used Claude to design a drug. The experiment has spawned a new investment thesis.

For years, artificial-intelligence evangelists have boasted about the technology’s capacity to revolutionize drug development and medical research.

Read the full article on MarketWatch ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.marketwatch.com — the content belongs to MarketWatch.

Wall Street researchers just used Claude to design a drug. The experiment has spawned a new investment thesis.

More from MarketWatch

It’s no secret what the best financial advice for retirement is — but most people ignore it anyway

Netflix vows to revive viewership trends, but investors hit ‘sell’ on the stock

Bull markets tend to peak with a whimper, not a bang — but a 15% correction for the S&P 500 may be next

The Social Security Administration corrected millions of records, and says there’s more to fix

More in Business

SpaceX revenue jumps 161% driven by Starlink and AI: Live updates

SpaceX says its capex could double this quarter as AI spending grows

Starlink's subscriber growth missed. Its profits didn't.

Boeing wins FAA approval for 737 Max 10 after years of delays as Duffy says certification process should be faster

Netflix posts higher Q3 profit but revenue growth worries pull shares lower

It’s no secret what the best financial advice for retirement is — but most people ignore it anyway